A private investment group that was founded by a family office has teams based in USA and Asia. The group is actively seeking new investments in the life sciences. The group invests broadly in therapeutics and digital health. The investment size will vary and typically it ranges from single to double digit millions. The group has no set number of allocations over the next 6-9 months.
In life sciences, the firm’s US team is looking for new investments in digital health and therapeutics. For therapeutics, the group is modality and indication agnostic. The group invests in both preclinical and clinical stage companies. The group is open to lead or syndicate with other investors.
The firm invests in privately-held life science companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Longevity Mandate: East Coast Based VC Fund
The firm is a New York based early-stage fund founded in 2019. The firm is affiliated with, but separate from, a New York based university, leveraging the network of schools and 70,000 + alumni network to
help their portfolio companies. The firm invests in technology-based companies in the pre-seed and seed stage, and while they prefer the companies have some revenue, they will invest in pre-revenue companies. The firm invests in several verticals, including Seniors and Tech, PropTech, Fintech, Cybersecurity, HealthTech and AI/ML. The firm does not invest in therapeutics or medical devices. The firm invests in North America and in Israel, with check size between $50-150K into rounds with a pre-money valuation of $2-10M.
Within HealthTech, the firm invests in Seniors and Tech and digital health. For digital health, the company is interested primarily in B2B models, but will invest in B2B2C as well. The firm has a special interest in Agetech, as one of the GPs is third generation senior living owner/operator.
The firm does not lead rounds, but is a very active investor alongside top-tier funds. Due to their strategic value, they are asked to serve in an advisory capacity. The firm prides itself on being a valued strategic partner. The firm will invest in new or seasoned entrepreneurs, who have assembled exceptional teams.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Hot Longevity Mandate: West Coast Based VC Fund
The firm is based in San Francisco, CA, and has an additional office in Japan. The firm is investing from a new fund that closed in 2016. The firm generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment. The firm invests 70% of its capital in the USA and Israel, with the remaining 30% in Japan. Under certain circumstances, the firm will invest outside those regions.
The firm invests in advanced therapeutics, healthcare IT, novel (sensor based IoT) devices and diagnostics, and second generation tools and technologies in the biotech R&D/laboratory innovation field. The firm is open to any indication area, and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer. The firm prefers to invest in technologies at an early stage of development.
The firm is interested in working with high quality management teams.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Hot Longevity Mandate: UK-Based Family Office
The firm is an active early stage venture fund based in the UK and Switzerland. The team is composed of experienced professionals in funding, entrepreneurship and therapeutic development. The firm has historically invested in computational biology, next generation tools for protein analysis and cell and gene therapy manufacturing technologies. Majority of technologies in the firm’s portfolio are relating to oncology, but going ahead the firm will consider any indication, if they find technology compelling. Firm has invested primarily in the UK and is willing to consider companies based in the broader Europe and in Switzerland in particular.
The firm is especially interested in companies developing therapeutic approaches, such as state of the art cell therapies that need local manufacturing, cancer vaccines, precision oncology medicine and novel therapies for autoimmune diseases. Delin Ventures is primarily interested in early stage, pre-clinical breakthrough technologies seeking seed investment.
The firm takes an active role with the companies in which they invest. The firm frequently leads rounds, and supports and mentors the early stage companies, often either taking a board seat themselves or finding an expert to serve on the board. Apart of building companies, the firm is also interested in the investment in the existing companies, syndicating with other investors
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Hot AI Mandate: Newly Established California-based VC Invests In Digital Health and AI-powered Healthcare Solutions
A newly established venture capital firm was founded in 2020 and is based in San Francisco, CA. The firm is expecting to close their first fund this year, targeting $100M. The firm is seeking to invest in Seed to Series A companies. The firm expects to make about 80% of their investments in North America, but has a global outlook and has evaluated opportunities from Israel, Japan, Europe, Asia, etc.
Within life sciences, the firm is most interested in digital health technologies, including Digital Therapeutics, AI-powered healthcare solutions, smart devices, and tech-enabled services. The firm will be extremely selective about medical device companies without a digital component. The same applies for traditional therapeutics and diagnostics sectors as well. The firm likes to see early traction (i.e. paying customer engagement), but is open to pre-revenue companies.
The firm is open to working with all kinds of management teams. The firm is capable of leading seed rounds and can act as either lead or co-investor. If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Hot AI Mandate: Boston-based VC Focuses on Early Stage Healthcare IT and Service Companies
Based in Boston and founded in 2006, a venture capital firm is currently investing from its fourth fund of $300 million closed in 2019. The firm typically is the lead or co-lead in the first institutional or Series A rounds in early-stage companies in the enterprise information technology (IT) space, including digital health. The firm’s equity investment size ranges from $3-7 million. The firm is most active on the US East Coast and would consider opportunities from across the US. The firm plans to make 5-7 new investments in the following year.
Within digital health, the firm is seeking systems, technologies, and services that support clinical delivery to improve outcomes and efficiency of clinical care. The firm is not interested in consumer-facing products, genomic analytics, or life sciences software – the focus is healthcare IT and services. The firm is looking for innovations that have demonstrated product-market fit in the form of recurring annual revenue of $1M or more. Pre-revenue companies may be considered if there is a strong fit with its investment thesis. When it comes to digital health investments, the firm often syndicates with strategic co-investors who understand the risks in the healthcare system, such as healthcare providers and payers.
The firm is looking for competent and experienced management teams with sector expertise. The firm brings in real-world experience, industry knowledge and networks, and company-building skills to its portfolio companies. The firm takes a board seat post-investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Hot AI Mandate: California-based Venture Capital Invests in Data-driven Technologies that Leverage AI, Machine Learning and IoT
A venture capital firm was founded in 2012 and is based in San Diego, CA. The firm invests in a wide range of data-driven products that integrate AI, machine learning, and IoT. The firm is backed by a management team with a long, successful track record of building tech companies. The firm invests in the company’s early stages with an initial check size of $250 K with follow-on investments as the company matures, with equity and convertible loan as the preferred capital structures. The firm focuses on US-based companies, but may consider international companies with strongly innovative products that they can bring to the US market.
The firm will look at a range of verticals in the life sciences sector as long as there is a strong data-driven component in the company’s product. Sectors of interest include healthcare IT/digital health. The firm will not consider therapeutics or medical devices unless there is a heavy data component. The firm’s previous investments include an AI-driven image analysis platform for cancer detection, a computational DNA analysis platform for personalized cancer treatments, and a DNA amplification technology based on electric field-induced pH changes. The firm has their own AI Lab of top data scientists, so the company does not have to have the AI experts as long as they have the data, know how to get the data, and what information would be valuable to retrieve via machine learning applications.
The firm will work with companies backed by founders with deep domain expertise. The firm prefers deploying the venture studio model to help co-found companies, deploy their AI Lab experts, and will always take a board seat in their portfolio companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 